Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001296549-26-000004·Allogene Therapeutics, Inc.
Schedule 13G ownership disclosure
Allogene Therapeutics Inc
Common Stock · CUSIP: 019770106
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Arie Belldegrun, M.D.
Shares: 13,248,170.00 · Class: 5.8%
- Bellco Legacy LLC
Shares: 539,867.00 · Class: 0.2%
- Bellco Legacy IV LLC
Shares: 4,710,120.00 · Class: 2.1%
- Vida Ventures LLC
Shares: 1,798,163.00 · Class: 0.8%
- Vida Ventures III, L.P.
Shares: 1,720,172.00 · Class: 0.8%
- Vida Ventures III-A, L.P.
Shares: 3,965.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001296549-26-000004
- Form type
- SCHEDULE 13G/A
- Filer
- Allogene Therapeutics, Inc.
- CIK
- CIK 1737287
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership